|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
49.550 -0.300 (-0.602%) | 2024/06 - Interim RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | 1,647,431 | 931,637 | 692,401 | 834,124 |
| Net Cash from / (used in) Investing Activities | -- | (527,282) | (858,737) | 1,563,266 | (521,119) |
| Net Cash from / (used in) Financing Activities | -- | 51,808 | (5,789,766) | 4,475,544 | (17,523) |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | 1,171,957 | (5,716,866) | 6,731,211 | 295,482 |
| Cash & Cash Equivalents at beginning of period | -- | 1,330,951 | 7,103,000 | 367,805 | 72,323 |
| Effect of Foreign Exchange Rate Changes | -- | 1,091 | (55,183) | 3,984 | 0 |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 2,503,999 | 1,330,951 | 7,103,000 | 367,805 |
| Remarks: | Real time quote last updated: 19/11/2024 09:56 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 983,164 |
| %Change | 47.414% |
| EPS / (LPS) | RMB 0.990 |
| NBV Per Share (¥) | RMB 5.806 |